Efficacy and Safety of Using Combination of 755-nm Picosecond Alexandrite Laser and 2% Hydroquinone Compared With 2% Hydroquinone Alone for the Treatment of Melasma: a Randomized Split-face Controlled Trial

Last updated: October 21, 2020
Sponsor: Mahidol University
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT04597203
si 082/2019
  • Ages 18-60
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

This study aims to assess the efficacy and safety of using combination of 755-nm picosecond alexandrite laser and 2% hydroquinone compared with 2% hydroquinone alone for the treatment of melasma: A randomized split-face controlled trial

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Both male and female age 18-60 years

  • Melasma on both cheeks - epidermal or mixed type

  • Fitzpatrick Skin type III-V

Exclusion

Exclusion Criteria:

  • History of retinoid or other keratolytic drugs used within 6 months before enrolled

  • History of keloid

  • photosensitivity

  • Immunocompromised host

Study Design

Total Participants: 20
Study Start date:
October 01, 2020
Estimated Completion Date:
February 28, 2021

Connect with a study center

  • Department of Dermatology, Siriraj Hospital, Mahidol University

    Bangkok, 10700
    Thailand

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.